Vincent Forlenza to Become BD's Next President, CEO | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Becton Dickinson today announced that its board has elected Vincent Forlenza to take over as the company's CEO starting Oct. 1, replacing Edward Ludwig.

Forlenza who joined BD in 1980 is currently president and chief operating officer at BD. He will remain President upon becoming the firm's CEO, BD said. Starting Oct. 1, he also will become a member of the board.

Ludwig will serve as executive chairman of the board starting Oct. 1 continuing through June 2012.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.